(NASDAQ: KNSA) Kiniksa Pharmaceuticals International's forecast annual revenue growth rate of 18.78% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.45%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.15%.
Kiniksa Pharmaceuticals International's revenue in 2026 is $945,963,000.On average, 9 Wall Street analysts forecast KNSA's revenue for 2026 to be $84,150,296,055, with the lowest KNSA revenue forecast at $80,614,569,330, and the highest KNSA revenue forecast at $86,821,734,025. On average, 9 Wall Street analysts forecast KNSA's revenue for 2027 to be $105,600,371,520, with the lowest KNSA revenue forecast at $95,071,763,050, and the highest KNSA revenue forecast at $113,536,113,725.
In 2028, KNSA is forecast to generate $124,064,722,195 in revenue, with the lowest revenue forecast at $106,228,945,160 and the highest revenue forecast at $140,250,493,425.